Barbara Leyman's most recent trade in Sutro Biopharma Inc was a trade of 25,000 Common Stock done . Disclosure was reported to the exchange on July 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sutro Biopharma Inc | Barbara Leyman | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 25,000 | 25,000 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Barbara Leyman | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 25,000 | 75,000 | - | - | Restricted Stock Units (RSUs) | |
| Sutro Biopharma Inc | Barbara Leyman | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.78 per share. | 08 Jul 2025 | 8,944 | 16,056 (0%) | 0% | 0.8 | 6,976 | Common Stock |
| Sutro Biopharma Inc | Barbara Leyman | Chief Business Dev. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2025 | 91,000 | 91,000 | - | - | Stock Option (Right to Buy) | |
| Sutro Biopharma Inc | Barbara Leyman | Chief Business Dev. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2025 | 84,500 | 84,500 | - | - | Restricted Stock Units (RSUs) | |
| Sutro Biopharma Inc | Barbara Leyman | Chief Business Dev. Officer | 08 Jul 2024 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy Common Stock) | ||
| Sutro Biopharma Inc | Barbara Leyman | Chief Business Dev. Officer | 08 Jul 2024 | 100,000 | 100,000 | - | - | Restricted Stock Units (RSUs) |